Brief: Vanda Pharmaceuticals Provides Update On Vqw-765 Clinical Development Program
14/10/2026 22:09
BRIEF-Vanda Pharmaceuticals Provides Update On Vqw-765 Clinical Development Program Oct 14 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:
VANDA PHARMACEUTICALS PROVIDES UPDATE ON VQW-765 CLINICAL DEVELOPMENT PROGRAM
VANDA PHARMACEUTICALS - PHASE III STUDY OF VQW-765 DID NOT MEET PRIMARY ENDPOINT IN SOCIAL ANXIETY DISORDER
VANDA PHARMACEUTICALS - VQW-765 FOUND SAFE AND WELL TOLERATED IN PHASE III STUDY
VANDA PHARMACEUTICALS - PHASE III STUDY DID NOT MEET KEY SECONDARY ENDPOINT IN FULL POPULATION
VANDA PHARMACEUTICALS - VQW-765 PROGRAM ON HOLD PENDING FURTHER ANALYSIS
Source text: ID:nPn7TRVsRa
Further company coverage: VNDA.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Vanda Pharmaceuticals
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program